生产企业：CanSino Biologics Inc.
PCV-24 (PCV24) is CanSino Biologics Inc.'s investigational 24-valent pneumococcal polysaccharide conjugate vaccine that utilizes a CRM197/tetanus toxoid dual-carrier technology platform; it is intended to help prevent infectious diseases caused by 24 pneumococcal serotypes and initiated Phase I/II clinical trials in May 2026.
PCV-24 (PCV24) is CanSino Biologics Inc.'s investigational 24-valent pneumococcal polysaccharide conjugate vaccine that utilizes a CRM197/tetanus toxoid dual-carrier technology platform; it is intended to help prevent infectious diseases caused by 24 pneumococcal serotypes and initiated Phase I/II clinical trials in May 2026.
共 1 项相关疾病
